AB
ESPR

Amalgamated Bank’s Esperion Therapeutics ESPR Stock Holding History

Amalgamated Bank’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,350
Closed -$27K – 2008
2025
Q4 		$27K Buy
7,350
+812
+12% +$2.62K ﹤0.01% 1999
2025
Q3 		$17K Hold
6,538
– – ﹤0.01% 2194
2025
Q2 		$6K Hold
6,538
– – ﹤0.01% 2644
2025
Q1 		$9K Hold
6,538
– – ﹤0.01% 2418
2024
Q4 		$14K Hold
6,538
– – ﹤0.01% 2268
2024
Q3 		$11K Hold
6,538
– – ﹤0.01% 2392
2024
Q2 		$15K Buy
+6,538
New +$15.4K ﹤0.01% 2230
2023
Q2 		– Sell
-10,454
Closed -$17K – 3059
2023
Q1 		$17K Sell
10,454
-2,036
-16% -$10.5K ﹤0.01% 2696
2022
Q4 		$78K Buy
12,490
+1,960
+19% +$14K ﹤0.01% 2235
2022
Q3 		$71K Buy
10,530
+569
+6% +$3.91K ﹤0.01% 2309
2022
Q2 		$63K Buy
9,961
+2,695
+37% +$15.3K ﹤0.01% 2365
2022
Q1 		$34K Buy
+7,266
New +$31.2K ﹤0.01% 2628
2020
Q3 		– Sell
-4,144
Closed -$213K – 1504
2020
Q2 		$213K Buy
+4,144
New +$173K 0.01% 1265
2020
Q1 		– Sell
-4,649
Closed -$277K – 1713
2019
Q4 		$277K Buy
+4,649
New +$209K 0.01% 1455
2019
Q3 		– Sell
-4,452
Closed -$207K – 1785
2019
Q2 		$207K Buy
+4,452
New +$209K ﹤0.01% 1575

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Amalgamated Bank's ESPR Position: Q1 2026 in Review

Amalgamated Bank sold out of Esperion Therapeutics (ESPR) in Q1 2026, closing a stake of 7,350 shares — an estimated $27K sold.

Amalgamated Bank first reported a position in ESPR in Q2 2019 and held it in 15 quarters. The position peaked at $277K in Q4 2019. 207 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Amalgamated Bank reported no remaining Esperion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 7,350 Esperion Therapeutics shares in Q1 2026, an estimated $27K.
  • Amalgamated Bank first reported a position in Esperion Therapeutics in Q2 2019 and held it in 15 quarters.
  • Amalgamated Bank's Esperion Therapeutics position peaked at $277K in Q4 2019.
  • 207 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.